Lupin awarded for Operational Excellence in Manufacturing at India Pharma Awards 2019

Pharma major Lupin Limited won the prestigious award for ‘Operational Excellence in Manufacturing’ at the India Pharma Awards 2019. The jury panel which comprised senior leaders and veterans from the industry, chose Lupin as the recipient of this award for the company’s innovative and consistent efforts in streamlining manufacturing operations and enabling quality excellence.

On receiving the award for operational excellence in manufacturing, Rajendra B Chunodkar, PresidentManufacturing Operations, Lupin Ltd. said, “We are delighted to receive this award. The award acknowledges our focus, commitment and efforts to deliver high-quality and affordable medicines globally. It reinforces our commitment to this mission and encourages us to set higher benchmarks in manufacturing and continuous improvement.”

Currently in its seventh year, the India Pharma Awards celebrates the advancements and achievements of the Indian Pharmaceutical Industry. The event was a part of the India Pharma Week 2019 held in Greater Noida (National Capital Region) between 26 – 28 November, 2019 and recognises companies and personnel from this industry. 

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. Lupin is the 8th largest generics pharmaceutical company by revenues, 3rd largest pharmaceutical player in the US by prescriptions, 3rd largest Indian pharmaceutical company by global revenues, 6th largest company in the Indian Pharmaceutical Market and 5th largest generic pharmaceutical player in Japan.

Website | + posts

HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.

What's your take on this post ? Comment: